Immediate antiinflammatory effects of inhaled budesonide in patients with asthma

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: In patients with asthma, single doses of inhaled glucocorticosteroids (ICS) have been reported to have antiinflammatory actions that can be detected several hours after drug administration. However, the onset and duration of the effect have not been investigated. We therefore measured airway blood flow (Q : aw) as an index of airway inflammation to determine the time course and dose dependence of the antiinflammatory action of an ICS in 20 patients with moderate asthma receiving regular ICS treatment. Methods:Q : aw and spirometry were measured before and serially for 360 minutes after a single inhaled dose of 360 μ, 720 μ, and 1,440 μ budesonide or placebo as well as after four repetitive 720-μ budesonide doses given 30 minutes apart. Results: Baseline mean Q : aw was increased and FEV1 was decreased without significant differences among the 5 treatment days. After budesonide inhalation, there was a transient, dosedependent decrease in mean Q : aw from 12 to 21%, with significant differences from baseline at 60 and 90 minutes for the 720-μ and 1,440-μ doses (P < 0.05). Thirty minutes after four repetitive budesonide administrations, mean Q : aw was 28% below baseline (P < 0.05) and remained 11% below baseline after 270 minutes. There was no change in mean FEV1 after any of the treatments. Conclusions: In subjects with moderate asthma who use ICS regularly, inhaled budesonide caused a transient dose-dependent vasoconstriction in the airway, thereby reversing one manifestation of airway inflammation. These results suggest that a pure controller medication can have immediate beneficial effects not paralleled by changes in airflow. Clinical trial registered with www.clinicaltrials.gov (NCT 01219738).

Original languageEnglish
Pages (from-to)706-711
Number of pages6
JournalAnnals of the American Thoracic Society
Volume11
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Budesonide
Anti-Inflammatory Agents
Asthma
Inflammation
Spirometry
Vasoconstriction
Inhalation
Therapeutics
Placebos
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Asthma
  • Bronchial circulation
  • Inhaled corticosteroids

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Immediate antiinflammatory effects of inhaled budesonide in patients with asthma. / Mendes, Eliana; Rebolledo, Patricia; Campos, Michael A; Wanner, Adam.

In: Annals of the American Thoracic Society, Vol. 11, No. 5, 01.01.2014, p. 706-711.

Research output: Contribution to journalArticle

@article{e30126aff7ba4d5592afeb63e2274681,
title = "Immediate antiinflammatory effects of inhaled budesonide in patients with asthma",
abstract = "Background: In patients with asthma, single doses of inhaled glucocorticosteroids (ICS) have been reported to have antiinflammatory actions that can be detected several hours after drug administration. However, the onset and duration of the effect have not been investigated. We therefore measured airway blood flow (Q : aw) as an index of airway inflammation to determine the time course and dose dependence of the antiinflammatory action of an ICS in 20 patients with moderate asthma receiving regular ICS treatment. Methods:Q : aw and spirometry were measured before and serially for 360 minutes after a single inhaled dose of 360 μ, 720 μ, and 1,440 μ budesonide or placebo as well as after four repetitive 720-μ budesonide doses given 30 minutes apart. Results: Baseline mean Q : aw was increased and FEV1 was decreased without significant differences among the 5 treatment days. After budesonide inhalation, there was a transient, dosedependent decrease in mean Q : aw from 12 to 21{\%}, with significant differences from baseline at 60 and 90 minutes for the 720-μ and 1,440-μ doses (P < 0.05). Thirty minutes after four repetitive budesonide administrations, mean Q : aw was 28{\%} below baseline (P < 0.05) and remained 11{\%} below baseline after 270 minutes. There was no change in mean FEV1 after any of the treatments. Conclusions: In subjects with moderate asthma who use ICS regularly, inhaled budesonide caused a transient dose-dependent vasoconstriction in the airway, thereby reversing one manifestation of airway inflammation. These results suggest that a pure controller medication can have immediate beneficial effects not paralleled by changes in airflow. Clinical trial registered with www.clinicaltrials.gov (NCT 01219738).",
keywords = "Asthma, Bronchial circulation, Inhaled corticosteroids",
author = "Eliana Mendes and Patricia Rebolledo and Campos, {Michael A} and Adam Wanner",
year = "2014",
month = "1",
day = "1",
doi = "10.1513/AnnalsATS.201307-220OC",
language = "English",
volume = "11",
pages = "706--711",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Immediate antiinflammatory effects of inhaled budesonide in patients with asthma

AU - Mendes, Eliana

AU - Rebolledo, Patricia

AU - Campos, Michael A

AU - Wanner, Adam

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: In patients with asthma, single doses of inhaled glucocorticosteroids (ICS) have been reported to have antiinflammatory actions that can be detected several hours after drug administration. However, the onset and duration of the effect have not been investigated. We therefore measured airway blood flow (Q : aw) as an index of airway inflammation to determine the time course and dose dependence of the antiinflammatory action of an ICS in 20 patients with moderate asthma receiving regular ICS treatment. Methods:Q : aw and spirometry were measured before and serially for 360 minutes after a single inhaled dose of 360 μ, 720 μ, and 1,440 μ budesonide or placebo as well as after four repetitive 720-μ budesonide doses given 30 minutes apart. Results: Baseline mean Q : aw was increased and FEV1 was decreased without significant differences among the 5 treatment days. After budesonide inhalation, there was a transient, dosedependent decrease in mean Q : aw from 12 to 21%, with significant differences from baseline at 60 and 90 minutes for the 720-μ and 1,440-μ doses (P < 0.05). Thirty minutes after four repetitive budesonide administrations, mean Q : aw was 28% below baseline (P < 0.05) and remained 11% below baseline after 270 minutes. There was no change in mean FEV1 after any of the treatments. Conclusions: In subjects with moderate asthma who use ICS regularly, inhaled budesonide caused a transient dose-dependent vasoconstriction in the airway, thereby reversing one manifestation of airway inflammation. These results suggest that a pure controller medication can have immediate beneficial effects not paralleled by changes in airflow. Clinical trial registered with www.clinicaltrials.gov (NCT 01219738).

AB - Background: In patients with asthma, single doses of inhaled glucocorticosteroids (ICS) have been reported to have antiinflammatory actions that can be detected several hours after drug administration. However, the onset and duration of the effect have not been investigated. We therefore measured airway blood flow (Q : aw) as an index of airway inflammation to determine the time course and dose dependence of the antiinflammatory action of an ICS in 20 patients with moderate asthma receiving regular ICS treatment. Methods:Q : aw and spirometry were measured before and serially for 360 minutes after a single inhaled dose of 360 μ, 720 μ, and 1,440 μ budesonide or placebo as well as after four repetitive 720-μ budesonide doses given 30 minutes apart. Results: Baseline mean Q : aw was increased and FEV1 was decreased without significant differences among the 5 treatment days. After budesonide inhalation, there was a transient, dosedependent decrease in mean Q : aw from 12 to 21%, with significant differences from baseline at 60 and 90 minutes for the 720-μ and 1,440-μ doses (P < 0.05). Thirty minutes after four repetitive budesonide administrations, mean Q : aw was 28% below baseline (P < 0.05) and remained 11% below baseline after 270 minutes. There was no change in mean FEV1 after any of the treatments. Conclusions: In subjects with moderate asthma who use ICS regularly, inhaled budesonide caused a transient dose-dependent vasoconstriction in the airway, thereby reversing one manifestation of airway inflammation. These results suggest that a pure controller medication can have immediate beneficial effects not paralleled by changes in airflow. Clinical trial registered with www.clinicaltrials.gov (NCT 01219738).

KW - Asthma

KW - Bronchial circulation

KW - Inhaled corticosteroids

UR - http://www.scopus.com/inward/record.url?scp=84903597411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903597411&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201307-220OC

DO - 10.1513/AnnalsATS.201307-220OC

M3 - Article

C2 - 24735128

AN - SCOPUS:84903597411

VL - 11

SP - 706

EP - 711

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 5

ER -